Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
Immunopharmacology and Immunotoxicology (2021) Vol. 44, Iss. 1, pp. 28-34
Open Access | Times Cited: 18

Showing 18 citing articles:

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Claudia M. Denkinger, Maike Janssen, Ulrike Schäkel, et al.
Nature Cancer (2022)
Open Access | Times Cited: 53
ORCHESTRA Delphi Consensus: Clinical Management of SARS-CoV-2 Infection in People with HIV
Alessandro Tavelli, Alessandra Vergori, A. Cingolani, et al.
Clinical Microbiology and Infection (2025)
Closed Access
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Arash Akbarzadeh, Behnam Amani, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 14
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
Sergio Fazio, Flora Affuso, Paolo Bellavite
Medical Science Monitor (2022) Vol. 28
Open Access | Times Cited: 17
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
Mahali S. Morgan, Kexin Yan, Thuy T. Le, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 139-139
Open Access | Times Cited: 17
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
CLINICAL EFFECTIVENESS OF CASIRIVIMAB AND IMDEVIMAB COMPARED WITH STANDARD OF CARE IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Amirhossein Orandi, Mojhgan Mohajeri, Mohsen Mansouri, et al.
Studies in Medical Sciences (2024) Vol. 34, Iss. 11, pp. 727-741
Open Access | Times Cited: 2
Clinical efficacy of anti‐SARS‐CoV‐2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta‐analysis
Danijela Miljanovic, Andja Ćirković, Ivana Lazarević, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 4
Closed Access | Times Cited: 5
Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study
Riccardo Nevola, Giovanni Feola, Rachele Ruocco, et al.
International Journal of Infectious Diseases (2023) Vol. 131, pp. 155-161
Open Access | Times Cited: 5
Risk of severe illness in patients infected with SARS-CoV-2 of Delta variant: a systematic review and meta-analysis
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
Infectious Diseases (2022) Vol. 54, Iss. 8, pp. 614-617
Open Access | Times Cited: 8
EFFECTIVENESS OF MOLNUPIRAVIR IN THE TREATMENT OF PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Morteza Zaboli Mahdiabadi, Chiman Karami, Elham Saber, et al.
Studies in Medical Sciences (2023) Vol. 33, Iss. 12, pp. 857-867
Open Access | Times Cited: 3
Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital
Erika A. Keshishian, Elizabeth Kuge, Jordan Memmott, et al.
Journal of Osteopathic Medicine (2022) Vol. 122, Iss. 12, pp. 635-640
Open Access | Times Cited: 4
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial
Claudia M. Denkinger, Maike Janssen, U. Schäkel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
Junichi Yoshida, Kenichiro Shiraishi, Masao Tanaka
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Coronaviruses: Pandemic SARS-CoV-2
Benjamin J. Cowling, Sook‐San Wong
Springer eBooks (2024), pp. 1-79
Closed Access
The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure?
Sergio Fazio, Marco Cosentino, Franca Marino, et al.
Journal of Pharmacy and Pharmacology Research (2022) Vol. 06, Iss. 03
Open Access | Times Cited: 3
Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
British Journal of Clinical Pharmacology (2023) Vol. 89, Iss. 4, pp. 1282-1290
Open Access
Preclinical and Human Phase 1 Studies of Aerosolized Hydroxychloroquine: Implications for Antiviral COVID-19 Therapy
Ohad S. Bentur, Richard Hutt, Donna Brassil, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Delays in COVID-19 Diagnosis and Hospitalization and Outcomes — New York City, New York, USA, October 2020–November 2021
Laura Graf, Eric Peterson, Jennifer Baumgartner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top